- Home
- ASTH vs CNTA Comparison
ASTH vs CNTA Comparison
Compare ASTH & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTH
- CNTA
- Stock Information
- Founded
- ASTH 1994
- CNTA 2020
- Country
- ASTH United States
- CNTA United Kingdom
- Employees
- ASTH N/A
- CNTA N/A
- Industry
- ASTH Professional Services
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- ASTH Consumer Discretionary
- CNTA Health Care
- Exchange
- ASTH Nasdaq
- CNTA Nasdaq
- Market Cap
- ASTH 2.0B
- CNTA 2.3B
- IPO Year
- ASTH N/A
- CNTA 2021
- Fundamental
- Price
- ASTH $37.14
- CNTA $16.46
- Analyst Decision
- ASTH Strong Buy
- CNTA Strong Buy
- Analyst Count
- ASTH 6
- CNTA 8
- Target Price
- ASTH $66.40
- CNTA $23.71
- AVG Volume (30 Days)
- ASTH 384.0K
- CNTA 470.8K
- Earning Date
- ASTH 02-25-2025
- CNTA 11-12-2024
- Dividend Yield
- ASTH N/A
- CNTA N/A
- EPS Growth
- ASTH 34.92
- CNTA N/A
- EPS
- ASTH 1.30
- CNTA N/A
- Revenue
- ASTH $1,722,367,000.00
- CNTA $6,853,000.00
- Revenue This Year
- ASTH $46.11
- CNTA N/A
- Revenue Next Year
- ASTH $34.25
- CNTA N/A
- P/E Ratio
- ASTH $28.80
- CNTA N/A
- Revenue Growth
- ASTH 29.71
- CNTA N/A
- 52 Week Low
- ASTH $29.08
- CNTA $7.38
- 52 Week High
- ASTH $63.20
- CNTA $18.97
- Technical
- Relative Strength Index (RSI)
- ASTH 59.31
- CNTA 50.86
- Support Level
- ASTH $30.86
- CNTA $14.61
- Resistance Level
- ASTH $32.86
- CNTA $17.65
- Average True Range (ATR)
- ASTH 1.61
- CNTA 1.08
- MACD
- ASTH 1.02
- CNTA -0.10
- Stochastic Oscillator
- ASTH 95.27
- CNTA 56.74
About ASTH Astrana Health Inc. Common Stock
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. Its operating segment is the healthcare delivery segment.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.